NDAINHALATIONAEROSOL, METEREDPriority Review
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
VANCERIL (beclomethasone dipropionate) by Merck & Co. is anti-inflammatory activity. Approved for asthma, allergic rhinitis. First approved in 1976.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCERIL (beclomethasone dipropionate) is an inhaled corticosteroid approved in 1976 for asthma and allergic rhinitis. It works via rapid hydrolysis to its active metabolite 17-BMP, which binds the glucocorticoid receptor with high affinity and inhibits inflammatory cells and mediators. The drug demonstrates a favorable ratio of topical anti-inflammatory to systemic corticosteroid effects at recommended doses.
LOE Approaching
Product is in late-stage maturity with LOE approaching; commercial teams are likely focused on generic transition planning and key account retention rather than growth initiatives.
Mechanism of Action
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indications (2)
Worked on VANCERIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.